Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology. The NBI is currently comprised of approximately 250 companies. For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated inclusion in the Nasdaq Biotechnology Index following the annual reconstitution, risks and uncertainties relating to the anticipated trading of Zymeworks securities, and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks relating to becoming included and remaining included in the Nasdaq Biotechnology Index; risks and uncertainties relating to the trading of our securities as it relates to the Nasdaq Biotechnology Index annual reconstitution and the inclusion of Zymeworks on the Nasdaq Biotechnology Index following such reconstitution; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; inability to maintain or enter into new partnerships or strategic collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the other risks described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:

Diana Papove
Director, Corporate Communications
(604) 678-1388
media@zymeworks.com



Zymeworks Added to Nasdaq Biotechnology Index

THỦ THUẬT HAY

Hướng dẫn tạo nhiều ảnh chất lượng chỉ với 1 bước đơn giản

Để tạo ra những bức ảnh chất lượng, bạn hãy truy cập trang web: Ephoto360.com trang tạo hiệu ứng ảnh nghệ thuật cung cấp cho các bạn công cụ tạo hiệu ứng ảnh, hiệu ứng chữ online đơn giản để có thể tạo cho mình được

Cách chơi Xuất Kích, game bắn súng trên nền web mới ra mắt

Xuất Kích là một tựa game MOBA bắn súng mới được ra mắt không lâu, trò chơi là một sự kết hợp hoàn hảo giữa bắn súng và chiến thuật.

Cách dùng Magicut trên iPhone với nhiều tính năng chỉnh video cực hot

Magicut là một ứng dụng chỉnh sửa video trên iPhone, iPad miễn phí và nhiều tính năng chỉnh sửa video hot. Sau đây là hướng dẫn cách dùng Magicut trên iPhone...

Hướng dẫn đăng nhập website bằng dấu vân tay trên điện thoại Samsung

Cảm biến dấu vân tay đang dần trở thành một công cụ không thể thiếu trên điện thoại thông minh với vô vàn tiện ích hấp dẫn. Ngoài khả năng khóa điện thoại nhanh chóng, an toàn, bạn còn có thể sử dụng cảm biến vân tay để

Dịch vụ mua traffic giải nén file - Traffic thực uy tín

Hiện nay, công cụ tìm kiếm đang xem vấn đề “lưu lượng truy cập website” rất quan trọng, lượng truy cập sẽ quyết định trang web của bạn có lên top công cụ tìm kiếm hay không. Nắm được những nỗi lo đó, TrafficSEO đã cho

ĐÁNH GIÁ NHANH

Đánh giá pin iPhone 13: Thời gian sử dụng xuất sắc, thời gian sạc còn hạn chế

Khi ra mắt iPhone 13, Apple cho biết pin của nó tốt hơn thế hệ tiền nhiệm. Vậy cụ thể như thế nào? Mời bạn cùng chúng tôi đánh giá pin iPhone 13 để biết thêm chi tiết nhé. iPhone 13 có dung lượng pin bao nhiêu? Để biết

Đánh giá hiệu năng Galaxy Tab S4: Đáp ứng tốt hầu hết mọi tác vụ sử dụng

Với Geekbench Galaxy Tab S4 đạt được số điểm 6.417, không quá ấn tượng, số điểm này tương đương với các thiết bị chạy Snapdragon 835 năm ngoái.

Ấn tượng đầu tiên về iPad Mini 6: Có nhiều điểm mới, giá chỉ từ 14,99 triệu đồng

Bên cạnh dòng sản phẩm iPhone 13, đồng hồ Apple Watch series 7, chúng ta còn có thêm chiếc máy tính bảng iPad Mini 6 với rất nhiều cải tiến và nâng cấp. Ấn tượng đầu tiên về iPad Mini 6 sau buổi ra mắt: thiết kế vuông